Alphatec Q3 revenue rises 13% to $221 million; net loss narrows to $5 million
Alphatec reported third-quarter 2026 revenue of $221 million, up 13% year-over-year, with a GAAP net loss of $5 million versus $29 million a year earlier. CEO Pat Miles said revenue fell short of the company's expectations, mainly due to lower biologics attachment, while surgical hardware and case volumes grew. The company now expects full-year 2026 total revenue of approximately $862 million and adjusted EBITDA of approximately $137 million.
Key points
- Total revenue $221 million, up 13% year-over-year; surgical revenue $202 million, up 14%
- GAAP net loss $5 million versus $29 million a year earlier; non-GAAP net income $15 million
- Adjusted EBITDA $38 million, 17.3% margin, up 400 basis points year-over-year
- FY2026 outlook: total revenue approximately $862 million, adjusted EBITDA approximately $137 million, free cash flow approximately $10 million
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.